Study on Adding Enasidenib to Standard Treatment for Higher-Risk Myelodysplastic Syndrome with IDH2 Mutation | Clinical Trial

Study on Adding Enasidenib to Standard Treatment for Higher-Risk Myelodysplastic Syndrome with IDH2 Mutation | Clinical Trial | Right2Hope